Home
overview
The conference will explore the ‘hot therapy areas’ being used in the treatment of arthritis including cytokine therapeutics, antibody therapeutics, kinase inhibitors and drugs that control or modify specific types of arthritis (DMARDs). This therapeutic focus will be accompanied by market overviews of the most successful types of treatment, an analysis of the global anti-arthritic market and an insight into the increasingly proactive role the ‘expert patient’ now demands.

The idea of optimising research capabilities is being addressed with an additional half-day workshop to take place on the 2nd May entitled ‘The increasing importance of e-R&D’ which will comprehensively outline the factors involved in the implementation of a successful e-R&D program.

Treatments that make living with arthritis easier are constantly developing and improving. For our part, as world-leaders in pharmaceutical conferences, SMi Pharma has identified the fast moving anti-arthritic market as a targeted sector for executives anxious to keep a close eye on the anti-inflammatory industry development.

As a key industry representative, you are aware of the commercial possibilities of this sector and how they could benefit your company. Couple this with the fantastic networking opportunities offered to all of our delegates and you can see that this second annual conference Advances in Anti-Arthritic Agents is an opportunity waiting to be exploited

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Prof K.D Rainsford

Prof K.D Rainsford, Chair, Biomedical Sciences & Director, Biomedical Research Centre, Sheffield Hallam University

9:10 BRIEF OVERVIEW OF TREATMENT

Dr Sharyn D’Souza

Dr Sharyn D’Souza, Associate Director, Skeletal Diseases, Kendle

  • Osteoarthritis - NSAIDs: mode of action & efficacy
  • -future Cox 2 inhibitors
  • Rheumatoid Arthritis - DMARDs: mode of action, efficacy & future
  • -Corticosteroids
  • -TNF inhibitors
  • New classes of agents under development for the treatment of arthritis
  • 9:40 MARKET ANALYSIS OF ANTI-ARTHRITIC AGENTS

    Dr Chris Donnellan

    Dr Chris Donnellan, Analyst, Datamonitor

  • The global anti-arthritic market
  • Key market drivers
  • The future outlook
  • 10:20 GENES IN RESEARCH

    Dr Scott Sundseth

    Dr Scott Sundseth, Clinical Discovery Genetics Advisor, GlaxoWellcome

  • The concept of multifactorial disease
  • The hunt for disease-susceptibility genes and drug targets
  • -genomic approaches
  • -genetic linkage studies of disease families
  • -candidate genes: association analysis in case/control populations
  • The future of the identification of disease-associated susceptibility genes in arthritic research
  • 11:00 Morning Coffee

    11:20 EMERGING DRUG TARGETS IN ARTHRITIC RESEARCH

    Dr John Lee

    Dr John Lee, Associate Director, Bone and Cartilage Biology, GlaxoSmithkline

  • Signal transduction pathways
  • Transcription factors in cartilage remodeling
  • Bone and cartilage selective proteases
  • Ion channels and anion sensing receptors
  • Bone specific cytokine antagonism
  • 12:00 NEW APPROACHES TO DEALING WITH RA

    Dr Nigel Phillips

    Dr Nigel Phillips, Senior Vice President, Chief Scientific Officer, Bioniche

  • Mycobacterial cell wall-mycobacterial DNA complex (MCC) as an immune modulator and anti-inflammatory agent
  • The mycobacterial DNA as an immune modulator and anti-inflammatory agent
  • Identification of oligonucleotide sequences (OligomodulatoryTM) with anti-profilerative, cell cycle arresting and immune modulatory activity
  • Structure-activity relationship of OligomodulatorsTM in the treatment of arthritis
  • 12:40 Networking Lunch

    13:40 AN ANTIBODY RESPONSE

    Dr Richard Jones

    Dr Richard Jones, Project Manager, Shire Pharmaceuticals

  • Clinical profile of an established selective COX-2 inhibitor
  • Experiences of the NILE COX-2 review
  • Future implications of COX-2 inhibitors
  • 14:20 ANTIBODY DEVELOPMENTS

    Dr Timo Veronna

    Dr Timo Veronna, Vice President, Drug Discovery, Biotie Therapies

  • Role of VAP-1 as an inflammation specific endothelial cell adhesion molecule recruiting subclasses of inflammatory cell to the inflamed synovium
  • Phase I clinical trial results from vepalimomab, a murine anti-VAP-1 monoclonal antibody in development for acute, severe inflammatory conditions
  • Status of the development program of the humanised anti-VAP-1 monoclonal antibody with a unique, improved constant region for rheumatoid arthritis
  • Introducing VAP-1 SSAO (semicarbazide sensitive amine oxidase) as a target for small molecule inhibitors
  • Status of the development program of VAP-1 SSAO inhibitors for rheumatoid arthritis
  • 15:00 KINASE INHIBITORS: THE NEXT GENERATION OF ANTI-ARTHRITIC AGENTS

    Dr George Schreiner

    Dr George Schreiner, Chief Scientific Officer, Scios

  • P38 Kinase, a key factor in the intracellular pathway that stimulates the synthesis of TNF alpha IL-1and Cox-2
  • The role oof p-29 kinase inhibitor in rheumatoid arthritis
  • Identifying the lead compounds that p38 kinase
  • The role of parallel processing in optimising small molecule compounds for clinical development
  • Scio 469: into the clinic
  • Advantages of a small molecule p38 kinase inhibitor in the treatment of autoimmune diseases
  • 15:40 Afternoon Tea

    16:00 AN ANTIBODY RESPONSE

    Dr Geoffrey Davies

    Dr Geoffrey Davies, Chief Scientific Officer, Abgenix

  • How ABX-IL8 has been developed using XenomouseTM technology
  • Evidence that IL-8 contributes to inflammatory disease
  • Targeting of Interleukin-8 to prevent inflammation
  • Results of clinical studies of ABX-IL8 in psoriasis
  • 16:30 ISSUES FOR CHRONIC TREATMENT WITH ANTIBODY THERAPIES

    Dr Ursula Ney

    Dr Ursula Ney, Director of Development, Celltech Chiroscience

  • Safety, efficacy and pk of antibodies for chronic therapy
  • Consequence of immune response generation
  • Use of engineered human antibodies for chronic use: repeat administration with CDP571, humanised anti-TNF
  • Commercial issues for chronic antibody use: supply, scale of manufacture, cost of goods, pricing
  • Microbial expression of antibody fragments for large scale production
  • Clinical evaluation of CDP870, a microbially expressed Fab’ conjugate
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Networking drinks reception

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Randall Stevens

    Dr Randall Stevens, Head, Clinical Sciences Infection & Inflammation, Hoffmann-La Roche

    9:10 CHANGING THE COURSE OF RHEUMATOID ARTHRITIS

    Dr Frank Douglas

    Dr Frank Douglas, Executive Vice President & Head of Drug Innovation and Approval, Aventis

  • Current therapies and how they treat the symptoms
  • Potential for Disease Modifying Antirheumatic Drugs (DMARD): retarding disease progression in rheumatoid arthritis
  • How can Leflunomide modify disease symptoms: radiographic and MRI assessment
  • Leflunnomide vs Methotrexate: a comparison of the American and European experience
  • Efficacy and safety of Leflunomide
  • 9:40 THERAPEUTIC OPTIONS FOR RA

    Evert Wallstrom

    Evert Wallstrom, Managing Director, Conpharm

  • The therapeutic properties of the Podophyllum plant
  • The development of CPH 82
  • Clinical trial efficacy in comparison with other DMARD market leaders
  • 10:20 THE DEVELOPMENT OF A SUCCESSFUL CYTOKINE RESPONSE

    Craig Smith

    Craig Smith, Project Manager, Immunex

  • Improving signs and slowing down the progression of rheumatoid arthritis
  • Developing Enbrel
  • Mechanism of action of Enbrel
  • Future applications of Enbrel
  • 11:00 Morning Coffee

    11:20 INTRINSICALLY ACTIVE

    Dr Richard Smith

    Dr Richard Smith, Chief Scientific Officer, AdproTech

  • Evolution of a generic membrane-targeting technology
  • Types of agent relevant to rheumatoid arthritis
  • Focus on regulation of complement activation
  • Development of an agent for use in man: pharmacology and production
  • Strategy for clinical progression
  • 12:00 TREATING RHEUMATOID ARTHRITIS

    Dr David Anderson

    Dr David Anderson, Chief Scientific Officer, Celgene

  • Using kinase inhibitors to effectively reduce excessive inflammation in arthritic joints
  • How C-Jun N-terminal kinase could suppress specific tissue distructive enzymes
  • The potential of C-Jun N-terminal kinase as therapeutic agents in the treatment of rheumatoid arthritis
  • Pharmacokinetic and pharmacodynamic properties of C-Jun N-terminal kinase
  • Pre-clinical trial status and results
  • 12:40 Networking Lunch

    13:40 VISCOSUPPLEMENT FOR OESTEOARTHRITIS OF THE KNEE

    Dr Stephen Ruskin

    Dr Stephen Ruskin, Vice President, Medical Affairs, Biomatrix

  • Analgesic effect on oesteoarthritis pain
  • Mode of action
  • Potential disease modifying effects
  • Long term clinical and health outcome benefits
  • Future research directions and anticipated applications
  • 14:20 DRUG DELIVERY TECHNOLOGIES

    Khawar Mann

    Khawar Mann, Director, Business Development, Weston Medical

  • Differentiation through drug delivery - the benefits
  • Alternative drug delivery technologies
  • Risk-return in drug delivery
  • 15:00 The Big Picture

    Dr Jim Weston

    Dr Jim Weston, General Manager, Cogent Diagnostics

  • The global anti-arthritic market
  • Key market drivers
  • The future outlook
  • 15:40 Afternoon Tea

    16:00 APPLICATIONS OF IMAGING IN CLINICAL TRIALS OF ARTHRITIS

    Dr Charles Peterfy

    Dr Charles Peterfy, Chief Medical Officer, Executive Vice President, SYNARC
    View Bio

  • When should imaging be used?
  • How can imaging accelerate clinical trials and reduce cost and uncertainty in drug development?
  • Choosing the right imaging technique for the purpose at hand
  • Integrating multicenter image acquisition with central image analysis
  • Which are the most promosing imaging markers for rheumatoid arthritis and osteoarthritis ?
  • Performance metrics for Clinical-Trials Radiology
  • 16:30 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    The increasing importance of e-R&D
    Workshop

    The increasing importance of e-R&D

    The Hatton, at etc. venues
    2nd May 2001
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.